Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 14,746 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pulmonary Clear all

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: fluticasone furoate/vilanterol, fluticasone furoate, vilanterol, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 16,568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 506
States / cities: Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 369 more

Conditions: Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions: Warfarin GenoSTAT Test; Device
Lead sponsor: Iverson Genetic Diagnostics, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 3,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 56
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more

Conditions: Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
Interventions: Radiotherapy, MEDI4736, Tremelimumab; Radiation · Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol/glycopyrrolate, indacaterol, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®); Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 110
States / cities: Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more

Conditions: COVID-19, Vaccine Reaction, COVID-19 Pandemic
Interventions: Moderna Booster Vaccine, Pfizer Booster Vaccine; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg, Placebo, Biological/Vaccine: BNT162b2 3mcg; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 6 Months to 15 Years
Enrollment: 11,837 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 90
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Carboplatin, Abequolixron, Abraxane, Pemetrexed; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Covid19
Interventions: Strength RMT, Strength RMT and nasal breathing, Endurance RMT, Endurance RMT and nasal breathing, Low dose RMT; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2,268 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 643 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Pulmonary Embolism
Interventions: Anticoagulant Therapy, Catheter-Directed Therapy; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 40
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 33 more

Conditions: Non Small Cell Lung Cancer, Lung Cancer, Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer
Interventions: S-3304, Chemo-irradiation; Drug · Other
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 5
States / cities: La Jolla, California • Washington D.C., District of Columbia • Kansas City, Kansas + 2 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium + olodaterol, tiotropium, olodaterol, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 2,624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 35
States / cities: Jasper, Alabama • Mobile, Alabama • Boulder, Colorado + 31 more

Conditions: Pediatric Feeding Disorder, Chronic, Avoidant Restrictive Food Intake Disorder
Interventions: Cyproheptadine, Nutritional Counseling, Behavioral Counseling; Drug · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 2 Years to 6 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lung Cancer, Head and Neck Cancer, Thyroid Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Colon Cancer, Rectum Cancer
Interventions: CARES Intervention; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 14
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 8 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Months to 13 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 4
States / cities: Los Angeles, California • Oakland, California • Houston, Texas

Conditions: Lung Cancer
Interventions: selenomethionine, carboplatin, paclitaxel, laboratory biomarker analysis, radiation therapy; Dietary Supplement · Drug · Other + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Non-squamous NSCLC, HER2 Exon 20 Mutation
Interventions: Pyrotinib, Docetaxel; Drug
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Orange, California • Sacramento, California • Whittier, California + 8 more

Conditions: Microbial Colonization, Ventilator Associated Pneumonia
Interventions: frequent standardized oral care; Other
Lead sponsor: University of Florida; Other
Eligibility: 12 Hours to 72 Hours
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone; Combination Product
Lead sponsor: Hal Chapman; Other
Eligibility: 40 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more

Conditions: Pulmonary Arterial Hypertension
Interventions: PAH Therapies; Other
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 15
States / cities: Brandon, Florida • Tampa, Florida • Chicago, Illinois + 12 more

Conditions: COVID-19
Interventions: Crisis management coaching; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Mental Health Issue, COVID-19
Interventions: in person meditation, in person meditation using headphones, virtual meditation; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut

Search by objective public record fields.

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Covid-19 Virtual Recovery Study

INHERIT EGFR - Studying Germline EGFR Mutations

Serological Surveillance for COVID-19 in Central North Carolina

Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

The Use of Cyproheptadine in Pediatric Feeding Disorders

Improving Care for Rural Patients With Solid Tumors

A Study of Two Forms of Pentamidine in HIV-Infected Children Who May Have Pneumocystis Carinii Pneumonia

Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Frequent Standardized Oral Care to Improve Health Outcomes in Premature Infants in the Neonatal Intensive Care Unit

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants

COPING With COVID-19( CWC-19)

Music Mindfulness Study 2a.